Please ensure Javascript is enabled for purposes of website accessibility

Health Care

Merck completes $11B Acceleron Pharma acquisition

“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” said Merck President and Chief Executive Officer Rob Davis of the $11.5 billion deal.

Read More »